Life Insurance With Autoimmune Disease: A 2026 SD Guide

Often, yes. A diagnosis of lupus, rheumatoid arthritis, multiple sclerosis, or Crohn’s disease does not automatically close the door on life insurance, even though it can feel that way the moment a doctor says the word “autoimmune.” What actually drives the outcome, according to two national carriers’ own published underwriting guides, is how long you’ve had the diagnosis, how active or controlled the disease is, which organs or systems it involves, and what your recent medical records show, not the diagnosis code by itself. This guide walks through how carriers in 2025 and 2026 actually underwrite these four autoimmune conditions, using real underwriting documents and federal and state health data, so you can find out where you likely stand instead of assuming the answer is no.

Why “I have an autoimmune disease, so I assume no” is the wrong starting point

Here’s the pain point in the words we actually hear: My rheumatologist said lupus, or RA, or MS, or Crohn’s, and I decided applying for life insurance would just end in rejection, so why bother. That reaction makes sense. Autoimmune conditions are chronic, they show up in medical records permanently, and the word “autoimmune” sounds like a single, scary category rather than four very different diseases with very different underwriting profiles. But that reaction also isn’t what the carriers’ own underwriting rules say will happen, and it keeps people from finding out what coverage they’d actually qualify for.

An autoimmune disease is a condition in which the immune system, which normally attacks bacteria and viruses, mistakenly attacks the body’s own healthy tissue. The four covered in this guide affect different systems: systemic lupus erythematosus (SLE), usually just called lupus, can affect the skin, joints, kidneys, and other organs, and varies enormously in severity from person to person. Rheumatoid arthritis (RA) primarily attacks the joints, causing inflammation, pain, and over time, potential joint damage. Multiple sclerosis (MS) attacks the protective coating around nerve fibers in the brain and spinal cord, which can affect movement, vision, and sensation, and it comes in patterns ranging from relapsing-remitting to steadily progressive. Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, causes chronic inflammation of the digestive tract; Crohn’s can affect any part of the digestive tract while ulcerative colitis is confined to the colon and rectum.

Underwriting is the process a life insurance company uses to evaluate an applicant’s risk and decide whether to offer coverage, at what price, and in which risk class, also called a rate class, a tier like Preferred Plus, Preferred, Standard Plus, or Standard that sets your premium relative to the carrier’s base rate. A table rating is a priced step above Standard, used for elevated but not disqualifying risk; the exact percentage added is set by each individual carrier. An Attending Physician Statement (APS) is a formal request for your medical records from your doctor or specialist, used whenever an underwriter needs more detail than the application provides; it is required in essentially every autoimmune-disease case at the carriers we reviewed. A contestability period is the window, two years under South Dakota law, during which an insurer can investigate and potentially deny a claim over a material misstatement on the application.

None of this underwriting logic is secret. Carriers publish underwriting field guides for their own agents, laying out in table form what best-case and worst-case outcomes look like for dozens of conditions, autoimmune diseases included. We pulled the current guides from two national carriers, Pacific Life Insurance Company and the Banner Life family of companies (Banner Life Insurance Company and William Penn Life Insurance Company of New York), to show what they actually say, in plain terms, with no guesswork filling the gaps.

How common are these conditions, really?

Before getting into the underwriting mechanics, it helps to see the scale of what’s being underwritten, because a lot of the fear behind this pain point comes from treating an autoimmune diagnosis as rare or unusual. It isn’t.

Sources: South Dakota Department of Health, Behavioral Risk Factor Surveillance System, Health Behaviors of South Dakotans 2023; CDC, MMWR 72(41):1101-1107, "Prevalence of Diagnosed Arthritis — United States, 2019-2021"; CDC-funded National Lupus Registry network pooled analysis (Georgia, Michigan, California, New York, and Indian Health Service registries), published estimate applied to 2018 Census data; CDC National Center for Health Statistics, Health E-Stat 122, "Inflammatory Bowel Disease Among Adults Age 18 and Older: United States, 2023-2024"; CDC, Preventing Chronic Disease 2010;7(1):A12, "The Prevalence of Multiple Sclerosis in 3 US Communities." Accessed October 2026.

Put plainly: more than one in four South Dakota adults carries some diagnosis on this broad spectrum, matching the national rate almost exactly. Lupus alone is estimated at roughly 204,300 people nationwide, concentrated heavily among women, nine times more likely to be affected than men according to the same CDC-funded registry data. Inflammatory bowel disease affects an estimated 4.1 million American adults. None of these are edge cases buried in a footnote of an underwriting manual. They are common enough that carriers underwrite them every day, with published rules for exactly how.

What underwriters actually look at, in their own published guides

This is the mechanism behind the pain point: people picture underwriting as a single box to check next to “autoimmune.” That isn’t how either guide we reviewed actually works, and it isn’t how any of these four conditions get evaluated.

Pacific Life’s Underwriting Guide (PLF4249-01, dated November 2025) lists each of the four conditions as its own line item, each requiring an Attending Physician Statement in all cases, each with its own stated outcome language. For rheumatoid arthritis, the guide states “Standard may be available,” with a decline reserved for “severe disabling disease or extensive organ involvement.” For colitis/ileitis, the category covering Crohn’s disease, regional enteritis, ulcerative colitis, and ulcerative proctitis, outcomes “vary by condition and control,” with “possible Standard for mild severity and limited colon involvement,” and a decline only “for severe attack within 1 year or surgery in last 6 months.” For multiple sclerosis, “Standard may be available for very stable, long-term disease,” with a decline reserved for “rapidly progressive disease.” Lupus/Systemic Lupus Erythematosus gets the most individualized language of the four: the outcome “depends on severity,” and “decline likely for systemic lupus with multiple organs involved,” which leaves meaningful room for a milder, more contained case.

Banner Life’s Field Guide for Life Insurance Underwriting (March 2026) takes a different approach, and the difference is worth knowing about before you assume every carrier documents conditions the same way. Its guide lists Systemic Lupus, Rheumatoid Arthritis, Multiple Sclerosis, and Inflammatory Bowel Disease (Ulcerative Colitis/Crohn’s) together on a list of conditions that “typically” require an Attending Physician Statement “at all ages and amounts” whenever the applicant has had a medical consultation for them. What the guide does not do is publish condition-specific outcome language the way Pacific Life’s guide does. Just as notably, none of the four conditions appears anywhere on Banner Life’s own published decline-and-postpone list, a separate, detailed list that does name dozens of other conditions and specific triggers, from cardiomyopathy to kidney failure to recent cancer treatment, by name and by threshold.

Sources: Pacific Life Insurance Company, Underwriting Guide: Confidence for Generations (PLF4249-01), November 2025; Banner Life family of companies (Banner Life Insurance Company and William Penn Life Insurance Company of New York), Field Guide for Life Insurance Underwriting, March 2026. Both guides state individual underwriting decisions depend on the full case and may differ from these examples. Every carrier sets its own guidelines; these two are shown as examples, not the full market.

The real takeaway from putting these side by side isn’t that one carrier is “better” for autoimmune disease in general. It’s that the two guides document the same four conditions at very different levels of detail, which means the carrier you apply to can change how much specific, written guidance exists before an underwriter ever opens your file. That’s exactly the kind of difference an independent comparison is built to catch.

Two worked, hypothetical examples

Take a hypothetical case: a 34-year-old Brookings resident was diagnosed with rheumatoid arthritis three years ago. She takes a single disease-modifying medication, has had no joint surgery, and her most recent rheumatology visit six months ago noted the disease as well-controlled with no new joint damage. She doesn’t smoke and has no other chronic conditions.

Under Pacific Life’s published guide, this case lines up with the language “Standard may be available,” since nothing in her file points toward “severe disabling disease or extensive organ involvement.” An Attending Physician Statement would still be required, as it is for every RA case, but a single well-controlled medication, a clean recent exam, and no surgical history work in her favor rather than against her. Under Banner Life’s guide, the same case would be evaluated after an APS is obtained, under the general framework that applies once records are reviewed; nothing in the published guide treats a well-managed, single-medication RA case as disqualifying.

Now take a different hypothetical: a 51-year-old Rapid City resident has Crohn’s disease with a flare and a bowel resection surgery four months ago, and is still adjusting medication with their gastroenterologist. Under Pacific Life’s guide, a surgery within the last six months lines up with the stated decline trigger, “decline for severe attack within 1 year or surgery in last 6 months,” which means this specific case, right now, is a likely decline or at minimum a postponement until there’s more time and stability behind it. That’s a real, useful piece of information: not “Crohn’s disease is uninsurable,” but “this specific recovery window is the wrong time to apply.” Waiting until the guide’s own stated thresholds, more distance from the surgery, a documented stable period, are met changes the picture considerably. Both examples are built to show how the mechanics work, not a benefit estimate or approval for any real applicant. Every case is evaluated on its own facts and its own test results, at whichever carrier it’s submitted to.

Compare both of those to the version of this story that keeps people from ever applying, or from timing it well: I have an autoimmune disease, so either I assume I’m stuck with the worst outcome, or I apply the moment I feel like it without checking what the guide actually rewards. Based on what these two carriers actually publish, the first assumption looks wrong for a well-controlled case, and the second mistake, applying at the worst possible moment, is avoidable once you know what the guide’s own thresholds are.

What it costs to guess wrong

The real cost here isn’t a specific premium figure; no honest source can quote you one without underwriting your actual file. It’s what happens when the assumption of “I’ll be declined” goes unchecked, at a scale that’s easy to underestimate given that 26% of South Dakota adults report some condition on this spectrum, per the state’s own 2023 health survey. Two outcomes tend to follow, and both are avoidable:

1. Going without coverage entirely, because applying feels pointless. If something happens to that person, the mortgage, the income replacement, the final expenses, none of it gets covered, not because they were actually uninsurable, but because they never found out.
2. Applying at the wrong moment, with only one carrier, treating a single company’s answer, or a single bad-timing decline, as the final word, when a different carrier’s guidelines, or simply a few more months of documented stability, could change the outcome entirely.

Both trace back to the same root problem: treating an assumption about an autoimmune diagnosis as a fact instead of checking it against what carriers actually publish, and against your own current stability. If you’d rather have someone local walk through your specific diagnosis and compare carrier options directly, that’s a conversation worth having before you decide coverage isn’t available to you. Compare My Options.

How to work through this yourself before you apply

Here’s the method, laid out step by step, no gatekeeping:

1. Write down your exact diagnosis and date. Lupus, RA, MS, or a specific form of IBD, and how long ago it was diagnosed. “Autoimmune disease” alone tells an underwriter almost nothing; the specific condition changes everything about how your case gets read.
2. Document severity and what’s involved. For lupus, which organs are affected, if any, beyond skin and joints. For RA, whether there’s joint damage or disability. For MS, the pattern (relapsing-remitting versus progressive) and how stable it’s been. For IBD, how much of the colon or digestive tract is involved and how recent any flare or surgery was.
3. List your current treatment. Medications, dosages, and how long you’ve been on your current regimen without a change. A single stable medication reads very differently to an underwriter than frequent treatment changes.
4. Pull your most recent specialist notes. A rheumatology, gastroenterology, or neurology visit from the last six to twelve months gives an underwriter something concrete to evaluate, rather than relying on the diagnosis alone.
5. Check the timing. Based on the guide language above, a recent flare, a recent surgery, or a recent diagnosis still being worked up is the wrong moment to apply at some carriers. A documented period of stability changes the picture considerably.
6. Answer every application question completely and honestly. South Dakota policies carry a two-year contestability period under SDCL 58-15-10, during which an insurer can investigate a claim and deny it for a material misstatement. Leaving something out to improve your odds up front creates real risk for your beneficiaries later.
7. Compare more than one carrier before drawing a conclusion. The side-by-side table above shows one carrier documents each condition by name with stated outcomes, while another requires the same records without publishing condition-specific criteria. If one company’s guide reads more cautiously than you expected, that isn’t necessarily the final answer across the market.

How we help

We’re an independent agency, which means we aren’t tied to one carrier’s risk appetite or its documentation style. When lupus, RA, MS, or Crohn’s is part of someone’s picture, that independence is exactly the point: instead of taking one company’s guidelines as the final word, or applying at the wrong moment, we can look at how different carriers actually treat your specific diagnosis, severity, and timing, and compare the real options side by side. We start with your specifics, the condition, the organs or systems involved, the treatment history, not a guess, and work from there. If you have a health condition you’ve assumed disqualifies you, it’s worth asking; independent agencies see how different carriers treat the same file. Compare My Options.

What you get

An actual underwriting answer instead of an assumption you never checked. A comparison across carriers instead of one company’s guidelines standing in for “what’s possible.” And, if coverage makes sense once you have real numbers and real timing in front of you, a policy sized to your actual situation rather than whatever felt safest to guess at.

Related reading

If a different chronic condition is the concern, see our guides on life insurance with heart disease, life insurance with diabetes, and life insurance with a mental health history. For the broader picture on how carriers are handling health conditions generally in 2026, see getting life insurance after a health condition. If you’re weighing the exam-free path, see underwritten vs. no-exam life insurance and how no-medical-exam life insurance actually works.

Frequently asked questions

Can you get life insurance if you have lupus, rheumatoid arthritis, MS, or Crohn’s disease?

Often, yes. Pacific Life’s current underwriting guide states that Standard classes may be available for rheumatoid arthritis, for mild colitis or Crohn’s disease with limited colon involvement, and for multiple sclerosis that is very stable and long-term. Lupus is evaluated more individually, with the outcome depending on severity; the guide notes a decline is likely only when lupus involves multiple organs. None of the four conditions is an automatic decline at either of the two carriers whose guides we reviewed.

Which autoimmune conditions require a medical records request (an APS)?

All four. Pacific Life’s guide requires an Attending Physician Statement for all cases of lupus, rheumatoid arthritis, multiple sclerosis, and colitis/ileitis (the category covering Crohn’s disease, regional enteritis, ulcerative colitis, and ulcerative proctitis). Banner Life’s guide lists Systemic Lupus, Rheumatoid Arthritis, Multiple Sclerosis, and Inflammatory Bowel Disease among the conditions that typically require an APS at all ages and amounts. Neither guide treats this as unusual; it is the standard step for any of these diagnoses.

Is a diagnosis of lupus or MS an automatic decline?

No, not under either guide we reviewed. Pacific Life’s guide ties its decline language to specific severity markers, systemic lupus with multiple organs involved, or rapidly progressive multiple sclerosis, not the diagnosis itself. Banner Life’s published decline-and-postpone list, which names dozens of conditions and triggers by name, does not include lupus, rheumatoid arthritis, multiple sclerosis, or inflammatory bowel disease anywhere on it.

How common are these conditions, really?

Common enough that carriers underwrite them routinely. In South Dakota, 26% of adults have been told by a health professional they have some form of arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia, according to the South Dakota Department of Health’s 2023 Behavioral Risk Factor Surveillance System report, matching the 26% nationwide median in that same report. Nationally, CDC’s 2019-2021 survey data put diagnosed arthritis (the same broad category) at 21.2% of adults, about 53.2 million people. For inflammatory bowel disease specifically, the CDC’s National Center for Health Statistics estimated 1.6% of U.S. adults, about 4.1 million people, had ever been diagnosed with Crohn’s disease or ulcerative colitis combined, using 2023-2024 survey data.

What is a table rating, and would one of these conditions put me in one?

A table rating is a priced step above a carrier’s Standard rate class, used when combined risk factors are elevated but not disqualifying. It is not a decline. Whether any of these four conditions results in a table rating, a Standard rate, or something closer to Preferred depends on the specific carrier and the details of your case: how long you have been diagnosed, how active or controlled the disease is, which organs or systems are involved, and what your treatment and monitoring history shows.

Will a decline from one carrier follow me to every other carrier?

No. SDCL 58-33-26 prohibits an insurer from unfairly discriminating between insureds with genuinely similar risk characteristics, but it does not require every company to use identical underwriting thresholds, and they don’t. Pacific Life’s guide documents named outcomes for each of these four conditions; Banner Life’s guide requires records for the same four conditions but does not publish condition-specific outcome language for them. A cautious answer from one company reflects that company’s own guidelines for your specific file, not a verdict on your insurability everywhere.

Does an old diagnosis ever stop mattering for a policy you already hold?

For a policy already in force, yes, in a specific legal sense. SDCL 58-15-10 requires South Dakota life insurance policies to become incontestable, except for fraud or nonpayment of premium, once the policy has been in force for two years from its issue date. After that two-year mark, the insurer generally cannot rescind the policy over an application misstatement discovered later. That protects coverage you already hold; it has no bearing on how a new application is underwritten.

Sources

• South Dakota Department of Health — Health Behaviors of South Dakotans 2023 (BRFSS) — 26% of South Dakota adults told they have some form of arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia, matching the 26% nationwide median; 2023 data; accessed October 2026
• CDC — MMWR 72(41):1101-1107, “Prevalence of Diagnosed Arthritis — United States, 2019-2021” — 21.2% of U.S. adults (53.2 million) had diagnosed arthritis, a category including rheumatoid arthritis, gout, lupus, and fibromyalgia; 2019-2021 National Health Interview Survey data; accessed October 2026
• National Lupus Registry network pooled analysis — PMC8169527 — pooled SLE prevalence of 72.8 per 100,000, an estimated 204,295 U.S. cases in 2018, and a ninefold higher rate in women (128.7 per 100,000) than men (14.6 per 100,000); CDC-funded four-state registry network plus an Indian Health Service registry; case-finding 2002-2009; accessed October 2026
• CDC National Center for Health Statistics — Health E-Stat 122, “Inflammatory Bowel Disease Among Adults Age 18 and Older: United States, 2023-2024” — 1.6% of U.S. adults (about 4.1 million) ever diagnosed with any inflammatory bowel disease; 0.5% (about 1.3 million) with Crohn’s disease; 1.2% (about 3.1 million) with ulcerative colitis; 2023-2024 National Health Interview Survey; accessed October 2026
• CDC — Preventing Chronic Disease 2010;7(1):A12, “The Prevalence of Multiple Sclerosis in 3 US Communities” — age-adjusted MS prevalence of 47.2 per 100,000 (Texas study area), 86.3 per 100,000 (Missouri study area), and 109.5 per 100,000 (Ohio study area); medical-records case-finding, 1998-2000; published January 2010; accessed October 2026
• Pacific Life Insurance Company — Underwriting Guide: Confidence for Generations (PLF4249-01) — November 2025 edition; Rheumatoid Arthritis, Lupus/Systemic Lupus Erythematosus, Multiple Sclerosis, and Colitis/Ileitis underwriting criteria; accessed October 2026
• Banner Life family of companies — Field Guide for Life Insurance Underwriting — March 2026 edition; APS-required conditions list including Systemic Lupus, Rheumatoid Arthritis, Multiple Sclerosis, and Inflammatory Bowel Disease; declines-and-postpones list; accessed October 2026
• South Dakota Legislature — SDCL 58-15-10, Incontestability provision required — two-year incontestability period for South Dakota life insurance policies, except fraud or nonpayment of premium; accessed October 2026
• South Dakota Legislature — SDCL 58-33-26, Unfair discrimination as to terms and conditions of insurance — prohibits unfair discrimination between insureds with like risk characteristics; accessed October 2026

Related reading: life insurance with heart disease, life insurance with diabetes, life insurance with a mental health history, getting life insurance after a health condition, underwritten vs. no-exam life insurance, and no-medical-exam life insurance in South Dakota.

The specifics and the timing decide this, not the diagnosis

Most people who assume an autoimmune diagnosis closes the door on life insurance have never actually checked, because the fear of a “no” feels worse than not asking. What the two carriers’ own published guides show is more specific, and less bleak, than that fear: the exact condition, its severity, which organs or systems it involves, your current treatment, and your timing relative to any recent flare or surgery, not the word “autoimmune” by itself. You can write down your own specifics this week, the diagnosis, the medications, the last specialist visit, and see how they line up against the guidelines above. That comparison is worth more than another year of guessing.